This clinical trial is focused on studying the effects of a medication called Obinutuzumab in patients with a condition known as Systemic Lupus Erythematosus (SLE). SLE is an autoimmune disease, which means the body’s immune system mistakenly attacks its own tissues, causing inflammation and damage to various parts of the body. The study aims to evaluate how effective and safe Obinutuzumab is for people with SLE. Participants in the study will receive either Obinutuzumab or a placebo, which is a substance with no active medication.

The study will be conducted over a period of time, during which participants will receive the treatment through an intravenous infusion, meaning the medication is given directly into a vein. The study will monitor the participants’ response to the treatment, looking at various health indicators to determine if the medication helps reduce the symptoms of SLE. The goal is to see if Obinutuzumab can help more people achieve a better state of health compared to those who do not receive the active medication.

Throughout the study, participants will be regularly assessed to track their progress and any changes in their condition. The study will also keep an eye on any side effects or adverse events that may occur. By the end of the study, researchers hope to gather enough information to understand the potential benefits and risks of using Obinutuzumab for treating Systemic Lupus Erythematosus.